Related Experiment Video
Updated: Sep 16, 2025
06:47
Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment
Published on: September 27, 2017
9.8K
NFATc1 deficiency in B cells ameliorates atopic dermatitis.
Hidaya Abdul Kader1, Syed Sabih Ur Rehman1, Dhanya Saraswathiamma2
1Department of Biology, College of Science, United Arab Emirates University, 15551, Al Ain, United Arab Emirates.
Scientific Reports
|July 11, 2025
Summary
Targeting NFATc1 in B cells reduces atopic dermatitis (AD) symptoms by increasing anti-inflammatory IL-10. This approach alleviates skin inflammation without impairing B-cell function, offering a novel therapeutic strategy for AD.
Area of Science:
- Immunology
- Dermatology
- Molecular Biology
Background:
- Atopic dermatitis (AD) is a prevalent global skin condition with no current cure.
- NFATc1 is a transcription factor crucial for immune function, known to suppress IL-10 in B cells.
- Understanding NFATc1's role in B cells is key to developing new AD treatments.
Purpose of the Study:
- To investigate the role of NFATc1-deficient B cells in a mouse model of atopic dermatitis.
- To determine if NFATc1 deficiency impacts AD phenotype and IL-10 production in B cells.
- To explore the transcriptomic changes in NFATc1-deficient B cells during AD.
Main Methods:
- Utilized Nfatc1-deficient (Nfatc1f/f x mb1cre) and wild-type (WT) AD mouse models.
- Administered calcipotriol to induce AD-like skin inflammation.
- Analyzed AD phenotype (ear swelling, epidermal thickness, cellular infiltration), IgE levels, B cell populations (Bregs), IL-10 production, and gene expression profiles.
Main Results:
- Nfatc1f/f x mb1cre AD mice showed significantly reduced AD symptoms compared to WT AD mice.
- NFATc1 deficiency in B cells led to an increased percentage of IL-10-producing B cells (Bregs).
- Transcriptome analysis revealed distinct gene expression patterns in NFATc1-deficient B cells, favoring B-cell development and stress responses.
Conclusions:
- NFATc1 deficiency in B cells promotes the differentiation of IL-10-producing Bregs, effectively alleviating AD symptoms.
- Targeting NFATc1 presents a potential therapeutic strategy for AD, enhancing anti-inflammatory IL-10 production without compromising B-cell function.
- This study highlights the intricate role of NFATc1 in regulating B-cell responses and its therapeutic potential in atopic dermatitis.
Related Concept Videos
01:24T Cell Types and Functions
1.4K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.4K
02:26NF-κB-dependent Signaling Pathway
7.9K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.9K